Last updated: August 26, 2026
ADALAT CC is Bayer’s branded extended-release nifedipine product for hypertension and chronic stable angina. Its commercial trajectory has followed the standard lifecycle of an older cardiovascular drug: strong pre-generic demand, erosion after broad generic entry, continued use in selected markets, and limited current strategic importance to the originator. In the United States, nifedipine extended-release tablets remain available through generic manufacturers, while ADALAT CC no longer has meaningful market exclusivity.
What is ADALAT CC and how does it work?
ADALAT CC contains nifedipine, a dihydropyridine calcium-channel blocker. The product uses a controlled-release delivery system intended to provide once-daily exposure.
| Attribute |
ADALAT CC |
| Active ingredient |
Nifedipine |
| Drug class |
Dihydropyridine calcium-channel blocker |
| Dosage form |
Extended-release tablet |
| Common strengths |
30 mg, 60 mg, and 90 mg, depending on market |
| Primary indications |
Hypertension and chronic stable angina |
| Originator |
Bayer |
| U.S. regulatory application |
NDA 019684 |
| Primary competitors |
Generic nifedipine ER tablets, PROCARDIA XL, other modified-release nifedipine products |
| Biosimilar exposure |
None; ADALAT CC is a small-molecule drug |
The formulation is designed to release nifedipine over an extended period. Product labeling instructs patients to swallow the tablets whole rather than crush or chew them, because altered administration can affect drug release and exposure (U.S. Food and Drug Administration [FDA], n.d.-a).
What is the FDA regulatory status of ADALAT CC?
ADALAT CC was approved in the United States as a prescription extended-release nifedipine product. FDA labeling identifies its use for hypertension and chronic stable angina. Generic nifedipine extended-release tablets have been approved under abbreviated new drug applications, allowing manufacturers to rely on the reference product’s safety and efficacy record while demonstrating pharmaceutical equivalence and bioequivalence.
The commercial distinction is important:
- The branded reference product is ADALAT CC.
- Generic products are generally labeled as nifedipine extended-release tablets.
- FDA approval of generic versions does not preserve brand pricing power.
- Therapeutic substitution depends on state law, payer policy, prescriber preference, and pharmacy practice.
The product is not a biologic and does not face biosimilar competition. Its competitive risk comes from small-molecule generic substitution under the Abbreviated New Drug Application pathway.
When did ADALAT CC lose exclusivity?
ADALAT CC lost practical U.S. market exclusivity after expiration of its relevant active-ingredient and formulation protections and the launch of generic nifedipine extended-release products. The product is now a mature, off-patent medicine.
The key commercial sequence was:
| Period |
Market event |
Commercial effect |
| 1990s |
ADALAT CC established as a once-daily nifedipine product |
Premium branded positioning |
| Late 1990s to 2000s |
Regulatory and patent barriers began to weaken |
Generic entry risk increased |
| 2000s |
Generic nifedipine ER products entered the U.S. market |
Rapid price and share erosion |
| 2010s |
Broad generic availability across major markets |
Brand became a low-growth maintenance product |
| 2020s |
Mature generic market |
Limited standalone strategic value for Bayer |
Exact exclusivity dates vary by jurisdiction because patent terms, pediatric extensions, regulatory exclusivity, and product-specific listings differ. The commercial conclusion is consistent: ADALAT CC does not have current blocking exclusivity in the United States.
What patents protect ADALAT CC?
ADALAT CC historically relied on intellectual property covering nifedipine, controlled-release oral dosage forms, and manufacturing or delivery techniques. Those protections are no longer commercially effective in the United States.
Active-ingredient patents
Nifedipine was discovered and commercialized decades before the current generic market. Any original compound patent protection expired long ago. No active U.S. compound patent prevents generic nifedipine products from entering the market.
Formulation patents
The principal technical value of ADALAT CC was its modified-release formulation. Formulation patents can protect:
- Release-controlling matrices or coatings
- Drug-release rates
- Tablet composition
- Manufacturing processes
- Once-daily delivery profiles
- Stability and dissolution characteristics
Those patents may have delayed or complicated generic entry, but they do not create a current barrier to generic nifedipine ER products. The FDA Orange Book historically listed patent information for the reference product and its approved uses. Current Orange Book listings should be reviewed for the precise NDA status and any residual listing, but historical listing alone does not establish an enforceable present-day exclusion right (FDA, n.d.-b).
Method-of-use patents
ADALAT CC labeling covers hypertension and chronic stable angina. Method-of-use claims associated with these indications would be difficult to use today as a broad commercial barrier because the underlying therapeutic uses are long established and generic products are widely marketed.
A generic applicant could use a Section viii statement to carve out a patented indication where applicable. In the case of mature nifedipine products, indication carve-outs are less important than the absence of meaningful active patent protection.
How many patents currently cover ADALAT CC?
No current U.S. patent estate appears to provide commercially meaningful exclusivity for ADALAT CC as a product. Historical patents may remain visible in patent databases or archived regulatory records, but expired patents do not prevent generic approval or launch.
The practical assessment is:
| Patent category |
Current commercial barrier |
| Nifedipine compound patent |
None |
| Original product patent |
None |
| Controlled-release formulation patents |
No material U.S. barrier identified |
| Method-of-use patents |
No broad commercial barrier identified |
| Manufacturing patents |
Potentially relevant to individual processes, not the market product |
| Device or delivery-system patents |
Limited relevance to current tablet competition |
Were there Paragraph IV challenges to ADALAT CC?
Generic applicants historically could challenge listed patents through Paragraph IV certifications. A Paragraph IV certification asserts that a listed patent is invalid, unenforceable, or will not be infringed by the proposed generic product.
Publicly available market history indicates that generic nifedipine ER competition developed despite the branded formulation estate. The economic effect of any Paragraph IV litigation was ultimately overtaken by broad generic availability and patent expiry.
The more relevant present-day point is that Paragraph IV litigation is not a current commercial threat to ADALAT CC. Any remaining challenge would have limited value unless it affected a specific unexpired, Orange Book-listed patent, and no such broad blocking right is evident from the mature market structure.
What is the Orange Book status of ADALAT CC?
ADALAT CC is associated with an FDA reference product application for extended-release nifedipine. The Orange Book is relevant for:
- Reference product identification
- Therapeutic equivalence ratings
- Approved dosage forms and strengths
- Listed patents and regulatory exclusivity
- Generic competition under ANDA approvals
Generic nifedipine extended-release tablets have been approved as therapeutically equivalent or otherwise substitutable products where the FDA has assigned the applicable rating. The precise rating can vary by strength, manufacturer, and product presentation. Buyers and licensing teams should distinguish the reference product from authorized generic or independent generic versions in the current FDA database.
What litigation affects ADALAT CC?
ADALAT CC does not appear to have an active, market-defining U.S. patent litigation campaign. Litigation was more relevant during the period when generic manufacturers sought approval for extended-release nifedipine products and the originator sought to enforce formulation or process rights.
Current legal exposure is limited to ordinary pharmaceutical-market issues:
- Product liability
- Labeling and pharmacovigilance
- Manufacturing compliance
- Antitrust or commercial disputes
- Generic quality or supply matters
- Country-specific trademark and regulatory disputes
No current litigation appears capable of restoring brand exclusivity or materially changing the U.S. competitive structure.
How has ADALAT CC’s financial trajectory developed?
ADALAT CC’s financial trajectory reflects a shift from originator economics to generic-market economics.
Originator phase
Before generic substitution, ADALAT CC benefited from:
- Once-daily dosing
- Recognition of the Bayer brand
- Established use in hypertension
- Cardiovascular specialist familiarity
- Formulation differentiation versus immediate-release nifedipine
Branded pricing and physician prescribing supported substantial revenue in the mature cardiovascular market. The product’s value depended primarily on volume and chronic treatment duration rather than high launch pricing.
Generic erosion phase
Generic entry reduced the product’s economic value through:
- Lower reimbursement for generic nifedipine ER.
- Pharmacy-level substitution.
- Formulary preference for lower-cost alternatives.
- Declining promotional investment.
- Reduced physician sensitivity to the brand’s controlled-release positioning.
Revenue erosion normally occurs faster than unit erosion because price falls before all brand users switch. A residual branded segment may remain among patients, physicians, or markets with stronger brand loyalty, but that segment is usually commercially narrow.
Mature phase
Bayer’s current public reporting does not provide a consistently separate, detailed annual revenue line for ADALAT CC across recent reporting periods. Bayer reports product sales at portfolio or business-unit levels, and older product-level disclosures may not be directly comparable because of currency translation, regional sales, divestitures, and reporting changes (Bayer AG, various years).
The financial conclusion is therefore more reliable than any unsupported standalone revenue estimate:
- ADALAT CC is no longer a major growth driver for Bayer.
- Generic nifedipine ER captures most volume-sensitive demand.
- Brand revenue is likely concentrated in selected countries and channels.
- Manufacturing and commercial overhead must be tightly controlled for the brand to remain attractive.
- The product’s residual value is mainly cash generation, geographic rights, and portfolio fit.
What market dynamics affect nifedipine ER?
Generic price competition
Nifedipine ER is a mature oral solid with multiple potential suppliers. Competition is based on:
- Wholesale acquisition price
- Contracting terms
- Supply reliability
- FDA compliance history
- Pharmacy benefit manager placement
- National and regional distribution
- Ability to supply all marketed strengths
Generic prices can compress sharply when several suppliers compete. Shortages or manufacturing disruptions can temporarily improve pricing, but such gains are usually unstable.
Therapeutic substitution
Nifedipine ER competes with other antihypertensive classes, including:
- Amlodipine
- Felodipine
- ACE inhibitors
- Angiotensin receptor blockers
- Thiazide diuretics
- Beta blockers in selected indications
Amlodipine is a particularly important competitor because it is also once daily, widely genericized, and heavily used in hypertension. Nifedipine ER retains clinical relevance in certain patients, including some cases requiring a dihydropyridine calcium-channel blocker or pregnancy-related blood-pressure management, subject to physician judgment and product labeling.
Regional variation
The brand’s market position differs by country. In some markets, ADALAT remains a recognizable branded cardiovascular product. In others, the name has limited commercial relevance because national formularies prioritize generic nifedipine or alternative calcium-channel blockers.
Geographic value depends on:
- Local patent and regulatory history
- Brand-prescription habits
- Public reimbursement
- Generic substitution rules
- Bayer’s distribution rights
- Local manufacturing economics
What generic launch scenarios exist for ADALAT CC?
The U.S. generic market is already established, so the relevant scenarios concern share and supply rather than first entry.
| Scenario |
Probability |
Effect on ADALAT CC |
| Stable multi-source generic supply |
High |
Continued low-price erosion and limited brand share |
| Generic supplier consolidation |
Moderate |
Short-term pricing improvement but higher supply risk |
| Manufacturing shortage |
Possible |
Temporary brand or secondary-generic demand |
| New formulation entrant |
Low to moderate |
Additional price pressure |
| Brand relaunch with new positioning |
Low |
Requires evidence of clinical or adherence differentiation |
| Regulatory withdrawal or discontinuation |
Market-specific |
Could eliminate residual brand revenue |
A new entrant would face few patent barriers but would still need FDA approval, validated bioequivalence, compliant manufacturing, commercial distribution, and payer access.
How strong is the patent estate for ADALAT CC?
The current patent estate is weak from a market-exclusion perspective.
| Factor |
Assessment |
| Compound protection |
Expired |
| Formulation protection |
Expired or commercially non-blocking |
| Regulatory exclusivity |
Expired |
| Generic substitutability |
High |
| Litigation leverage |
Low |
| Manufacturing complexity |
Moderate but manageable |
| Brand recognition |
Still relevant in selected markets |
| Revenue durability |
Low to moderate, dependent on geography |
| Biosimilar risk |
Not applicable |
| Reimbursement pressure |
High |
The formulation may require controlled-release manufacturing capability, but technical manufacturing requirements are not equivalent to patent exclusivity. A manufacturer can face development and quality-control costs without encountering a legally enforceable barrier.
Which companies are challenging ADALAT CC commercially?
The relevant challengers are generic manufacturers rather than branded innovators. Depending on market and time period, suppliers of nifedipine ER products have included large generic companies and regional manufacturers approved by national regulators.
The competitive set includes:
- U.S. ANDA holders for nifedipine extended-release tablets
- European generic manufacturers
- Authorized or licensed suppliers
- Local manufacturers in emerging markets
- Suppliers of therapeutically substitutable calcium-channel blockers
The principal competitive advantage is not a novel molecule. It is reliable, low-cost supply supported by regulatory compliance and payer access.
What licensing deals affect ADALAT CC?
ADALAT CC has been commercialized through Bayer’s global pharmaceutical operations and regional distribution arrangements. Publicly disclosed recent licensing transactions are not a central part of the product’s current economics.
Potential transaction structures for a mature product include:
- Country-level commercialization licenses
- Divestiture of local marketing rights
- Supply and distribution agreements
- Brand transfer with manufacturing rights
- Authorized generic arrangements
- Portfolio sales involving multiple mature products
The value of such a transaction would be determined by net sales, manufacturing cost, remaining brand recognition, regulatory obligations, and geographic concentration. A stand-alone global transaction would likely be less attractive than a broader mature-products portfolio deal.
What is the revenue exposure for Bayer?
ADALAT CC is unlikely to represent material group-level revenue exposure for Bayer compared with its major pharmaceutical and crop-science products. Its economic importance is more likely to appear at the level of:
- Regional pharmaceutical sales
- Mature-product cash flow
- Manufacturing utilization
- Portfolio operating margin
- Distributor relationships
- Legacy brand management
A sharp decline in ADALAT CC sales would not be expected to materially affect Bayer’s consolidated financial outlook. It could still matter to a regional licensee or contract manufacturer whose revenue is concentrated in mature cardiovascular products.
Key Takeaways
- ADALAT CC is Bayer’s branded extended-release nifedipine product.
- U.S. exclusivity has ended, and generic nifedipine ER products are widely available.
- The original compound and formulation protections no longer create a meaningful market barrier.
- Current competition is based on price, supply reliability, reimbursement, and distribution.
- Biosimilar risk does not apply because nifedipine is a small-molecule drug.
- Recent Bayer public filings do not provide a consistently separate annual revenue series for ADALAT CC.
- The product is a mature cash-flow asset with limited strategic growth potential.
- Residual value depends on country-specific brand loyalty, reimbursement, and manufacturing economics.
- No active patent litigation appears likely to restore ADALAT CC exclusivity.
- Generic launch risk is largely a historical issue in the United States and an ongoing substitution issue in international markets.
FAQs
Is ADALAT CC the same as nifedipine extended release?
ADALAT CC is a branded nifedipine extended-release product. Generic nifedipine ER tablets contain the same active ingredient but may use different inactive ingredients and release technologies, subject to regulatory equivalence requirements.
Can ADALAT CC still be prescribed after generic approval?
Yes. Physicians can prescribe the brand where it remains marketed and available. Insurance plans and pharmacies may prefer or substitute a generic version.
Does ADALAT CC have pediatric exclusivity?
No current pediatric exclusivity protects ADALAT CC in the U.S. Any historical regulatory exclusivity would have expired.
Is ADALAT CC authorized for immediate-release nifedipine substitution?
No. Extended-release ADALAT CC should not be treated as interchangeable with immediate-release nifedipine solely because both contain nifedipine. Release characteristics, dosing, and labeling differ.
Could Bayer sell the ADALAT brand?
A country-level or portfolio transaction is commercially possible for a mature brand. The value would depend on residual sales, local trademark rights, regulatory ownership, supply obligations, and profitability rather than patent exclusivity.
References
-
Bayer AG. (Various years). Annual reports and financial statements. Bayer AG.
-
U.S. Food and Drug Administration. (n.d.-a). ADALAT CC prescribing information. FDA.
-
U.S. Food and Drug Administration. (n.d.-b). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.
-
U.S. Food and Drug Administration. (n.d.-c). Drugs@FDA: FDA-approved drugs database. FDA.
-
U.S. Food and Drug Administration. (n.d.-d). Approved abbreviated new drug applications for nifedipine extended-release tablets. FDA.
